Immunocore (IMCR) Short Interest Ratio & Short Volume $35.93 -0.14 (-0.39%) Closing price 04:00 PM EasternExtended Trading$36.32 +0.38 (+1.07%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Immunocore Short Interest DataImmunocore (IMCR) has a short interest of 7.95 million shares, representing 16.35% of the float (the number of shares available for trading by the public). This marks a 0.00% change in short interest from the previous month. The short interest ratio (days to cover) is 22.4, indicating that it would take 22.4 days of the average trading volume of 369,943 shares to cover all short positions.Current Short Interest7,950,000 sharesPrevious Short Interest7,950,000 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$231.03 millionShort Interest Ratio22.4 Days to CoverLast Record DateMay 15, 2025Outstanding Shares50,234,000 sharesFloat Size48,620,000 sharesShort Percent of Float16.35%Today's Trading Volume509,274 sharesAverage Trading Volume369,943 sharesToday's Volume Vs. Average138% Short Selling Immunocore? Sign up to receive the latest short interest report for Immunocore and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIMCR Short Interest Over TimeIMCR Days to Cover Over TimeIMCR Percentage of Float Shorted Over Time Immunocore Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/20257,950,000 shares $231.03 million No Change16.4%22.4 $29.06 4/30/20257,950,000 shares $239.30 million +3.5%16.3%25.3 $30.10 4/15/20257,680,000 shares $209.74 million -5.0%15.8%25.1 $27.31 3/31/20258,080,000 shares $239.73 million +6.5%16.6%26.7 $29.67 3/15/20257,590,000 shares $218.59 million +2.2%17.2%26.6 $28.80 2/28/20257,430,000 shares $218.22 million +0.1%16.8%28.2 $29.37 2/15/20257,420,000 shares $219.63 million +1.1%16.8%28.8 $29.60 1/31/20257,340,000 shares $241.34 million +9.4%15.1%27.8 $32.88 1/15/20256,710,000 shares $197.54 million -0.3%13.8%24.4 $29.44 12/31/20246,730,000 shares $198.54 million -4.7%13.8%24.7 $29.50 Get the Latest News and Ratings for IMCR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter. 12/15/20247,060,000 shares $204.10 million -1.8%14.5%25.7 $28.91 11/30/20247,190,000 shares $235.40 million -5.4%14.8%25.9 $32.74 11/15/20247,600,000 shares $240.08 million -4.6%15.6%21.4 $31.59 10/31/20247,970,000 shares $245.72 million -4.3%16.4%21.6 $30.83 10/15/20248,330,000 shares $269.23 million -0.6%17.1%21.8 $32.32 9/30/20248,380,000 shares $260.87 million -1.0%17.2%20.8 $31.13 9/15/20248,460,000 shares $283.83 million +23.0%17.4%19 $33.55 8/31/20246,880,000 shares $246.85 million +16.2%14.2%13.2 $35.88 8/15/20245,920,000 shares $217.56 million +9.0%12.2%8.6 $36.75 7/31/20245,430,000 shares $215.57 million -6.2%11.2%7.3 $39.70 7/15/20245,790,000 shares $228.53 million -1.4%12.0%7.6 $39.47 6/30/20245,870,000 shares $198.93 million -5.5%12.1%7.5 $33.89 6/15/20246,210,000 shares $238.84 million -7.0%12.8%8.3 $38.46 5/31/20246,680,000 shares $327.19 million +29.2%13.8%9.5 $48.98 5/15/20245,170,000 shares $289.57 million +13.1%10.7%8.9 $56.01 4/30/20244,570,000 shares $270.00 million +11.7%9.4%11.2 $59.08 4/15/20244,090,000 shares $227.16 million -11.3%8.4%8.2 $55.54 3/31/20244,610,000 shares $299.65 million +7.5%9.5%9.4 $65.00 3/15/20244,290,000 shares $260.96 million +1.4%8.8%8.9 $60.83 2/29/20244,230,000 shares $284.34 million +9.6%8.7%8.6 $67.22 2/15/20243,860,000 shares $272.13 million +20.6%8.0%8.2 $70.50 1/31/20243,200,000 shares $231.33 million +8.1%6.6%6.7 $72.29 1/15/20242,960,000 shares $211.82 million +2.4%6.1%8 $71.56 12/31/20232,890,000 shares $197.44 million -13.0%6.0%8.4 $68.32 12/15/20233,320,000 shares $213.04 million -17.2%6.9%10.1 $64.17 11/30/20234,010,000 shares $211.45 million -3.4%8.3%13.1 $52.73 11/15/20234,150,000 shares $198.95 million +12.5%8.6%15.4 $47.94 10/31/20233,690,000 shares $163.84 million +7.3%8.0%14.2 $44.40 10/15/20233,440,000 shares $172.65 million +4.6%7.4%15 $50.19 9/30/20233,290,000 shares $170.75 million +3.8%7.1%14.9 $51.90Get Ready for Elon Musk’s BIGGEST Comeback Yet (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. Click here to see why Tesla's about to prove everyone wrong... again. 9/15/20233,170,000 shares $167.34 million +6.0%6.9%15.1 $52.79 8/31/20232,990,000 shares $168.25 million +4.2%6.2%15.2 $56.27 8/15/20232,870,000 shares $172.92 million +8.3%6.0%14.2 $60.25 7/31/20232,650,000 shares $174.85 million -4.7%5.8%12.8 $65.98 7/15/20232,780,000 shares $176.25 million No Change6.1%12 $63.40 6/30/20232,780,000 shares $166.69 million -4.1%6.1%11.5 $59.96 6/15/20232,900,000 shares $168.03 million +7.8%6.4%11.3 $57.94 5/31/20232,690,000 shares $148.43 million -5.0%5.7%10.2 $55.18 5/15/20232,830,000 shares $174.44 million +14.6%6.0%10.8 $61.64 4/30/20232,470,000 shares $143.38 million -1.6%5.3%9.5 $58.05 4/15/20232,510,000 shares $137.57 million +0.4%5.3%9.7 $54.81 3/31/20232,500,000 shares $123.60 million +8.7%5.3%9.5 $49.44 3/15/20232,300,000 shares $121.12 million +10.1%4.9%8.6 $52.66 2/28/20232,090,000 shares $114.64 million No Change4.5%6.9 $54.85 2/15/20232,090,000 shares $134.87 million No Change4.5%6.3 $64.53 1/31/20232,090,000 shares $128.05 million +8.9%4.5%5.8 $61.27 1/15/20231,920,000 shares $122.00 million +39.1%4.1%4.9 $63.54 12/30/20221,380,000 shares $78.76 million -28.5%3.0%3.6 $57.07 12/15/20221,930,000 shares $114.68 million +27.0%4.1%5.2 $59.42 11/30/20221,520,000 shares $95.47 million -9.5%3.3%3.9 $62.81 11/15/20221,680,000 shares $109.33 million -15.6%3.6%4.4 $65.08 10/31/20221,990,000 shares $113.71 million -13.9%5.2%6 $57.14 10/15/20222,310,000 shares $111.76 million +6.9%6.1%7.8 $48.38 9/30/20222,160,000 shares $101.39 million +27.8%5.7%7.7 $46.94 9/15/20221,690,000 shares $76.17 million +89.5%4.4%5.7 $45.07 8/31/2022891,800 shares $47.10 million -1.2%2.3%3.1 $52.81 8/15/2022902,500 shares $49.42 million -15.7%2.4%4.3 $54.76 7/31/20221,070,000 shares $49.37 million No Change2.8%4.9 $46.14 7/15/20221,070,000 shares $46.28 million +4.9%2.8%5 $43.25 6/30/20221,020,000 shares $38.06 million -4.7%2.4%4.8 $37.31 6/15/20221,070,000 shares $32.37 million -21.3%2.5%5.3 $30.25 5/31/20221,360,000 shares $38.56 million +18.3%3.2%7 $28.35 5/15/20221,150,000 shares $33.74 million +31.6%2.7%6.2 $29.34 4/30/2022873,800 shares $28.49 million -0.1%2.0%5.5 $32.61 4/15/2022874,300 shares $30.64 million +2.5%2.0%5 $35.05 3/31/2022852,700 shares $25.50 million +4.0%2.0%4.9 $29.90 3/15/2022820,000 shares $20.25 million +9.1%1.9%5.6 $24.70 2/28/2022751,900 shares $16.62 million +5.1%1.8%5.6 $22.10 2/15/2022715,500 shares $17.64 million +64.7%1.7%5.7 $24.66 1/31/2022434,400 shares $9.80 million +17.7%1.0%3.6 $22.57 1/15/2022369,200 shares $8.47 million -5.0%N/A3.5 $22.95 12/31/2021388,700 shares $13.31 million +5.4%0.9%5.5 $34.24 12/15/2021368,700 shares $11.99 million +144.5%0.9%5.8 $32.51 11/30/2021150,800 shares $5.43 million -1.3%0.4%2.5 $35.99 11/15/2021152,800 shares $5.97 million -17.8%0.4%2.5 $39.10 10/29/2021185,800 shares $7.16 million +9.6%0.4%2.6 $38.52 10/15/2021169,500 shares $6.44 million -50.1%0.4%2.4 $38.00 9/30/2021339,500 shares $12.59 million +131.6%0.8%4.8 $37.07 9/15/2021146,600 shares $4.74 million -12.6%0.3%2.1 $32.31 8/31/2021167,700 shares $5.80 million -53.9%0.4%2.4 $34.56Get Ready for Elon Musk’s BIGGEST Comeback Yet (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. Click here to see why Tesla's about to prove everyone wrong... again. 8/13/2021363,500 shares $11.17 million No Change0.9%6.1 $30.72 IMCR Short Interest - Frequently Asked Questions What is Immunocore's current short interest? Short interest is the volume of Immunocore shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 7,950,000 shares of IMCR short. 16.35% of Immunocore's shares are currently sold short. Learn More on Immunocore's current short interest. What is a good short interest ratio for Immunocore? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IMCR shares currently have a short interest ratio of 22.0. Learn More on Immunocore's short interest ratio. Which institutional investors are shorting Immunocore? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Immunocore: Caption Management LLC, Simplex Trading LLC, Wolverine Asset Management LLC, and Citigroup Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Immunocore? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 16.35% of Immunocore's floating shares are currently sold short. What is Immunocore's float size? Immunocore currently has issued a total of 50,234,000 shares. Some of Immunocore's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Immunocore currently has a public float of 48,620,000 shares. How does Immunocore's short interest compare to its competitors? 16.35% of Immunocore's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Immunocore: Revolution Medicines, Inc. (12.20%), Verona Pharma plc (10.60%), BridgeBio Pharma, Inc. (15.63%), Elanco Animal Health Incorporated (5.58%), Grifols, S.A. (1.46%), TG Therapeutics, Inc. (16.20%), Nuvalent, Inc. (13.13%), Legend Biotech Co. (4.15%), Lantheus Holdings, Inc. (11.74%), Axsome Therapeutics, Inc. (10.28%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($29.20 billion), Strategy Incorporated ($10.88 billion), iShares 20+ Year Treasury Bond ETF ($10.04 billion), Capital One Financial Co. ($5.51 billion), Charter Communications, Inc. ($5.00 billion), Super Micro Computer, Inc. ($4.43 billion), Apollo Global Management, Inc. ($4.02 billion), Hims & Hers Health, Inc. ($3.65 billion), VanEck Semiconductor ETF ($3.27 billion), and Coinbase Global, Inc. ($3.10 billion). View all of the most shorted stocks. What does it mean to sell short Immunocore stock? Short selling IMCR is an investing strategy that aims to generate trading profit from Immunocore as its price is falling. IMCR shares are trading down $0.14 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Immunocore? A short squeeze for Immunocore occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IMCR, which in turn drives the price of the stock up even further. How often is Immunocore's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMCR, twice per month. The most recent reporting period available is May, 15 2025. More Short Interest Resources from MarketBeat Related Companies Revolution Medicines Short Squeeze Verona Pharma Short Squeeze BridgeBio Pharma Short Squeeze Elanco Animal Health Short Squeeze Grifols Short Squeeze TG Therapeutics Short Squeeze Nuvalent Short Squeeze Legend Biotech Short Squeeze Lantheus Short Squeeze Axsome Therapeutics Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IMCR) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump Nominates “Next Elon”Elon's Replacement? You've been told Elon Musk has been forced out of DC. But did you know his successor ha...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMCR Stock Free IMCR Stock Alerts